Literature DB >> 2409225

The immune response to herpes simplex virus: comparison of the specificity and relative titers of serum antibodies directed against viral polypeptides following primary herpes simplex virus type 1 infections.

R Eberle, S W Mou, J A Zaia.   

Abstract

Employing an immunoblotting technique, the polypeptide specificity and relative titers of anti-HSV IgG reactive with denaturation-resistant epitopes on HSV proteins were determined in patients experiencing primary HSV-1 infections at various anatomical sites. Early sera from previously seronegative patients with primary HSV-1 infections were found to have comparatively low levels of antibody directed against the major viral glycoprotein antigens (gB, gC, and gD) relative to titers present in sera of individuals with long-standing, latent orofacial HSV-1 infections. Patients with primary infections did however have high titers of antibody directed against a series of low molecular weight HSV polypeptide antigens. These antigens were found to be antigenically related to a structural component of virion nucleocapsids. At later times postinfection, titers of antibodies directed against other viral polypeptides including the major glycoproteins increased to levels more closely approximating those observed in latently infected individuals. These results indicate that the anti-HSV IgG detected by immunoblot analysis which appears earliest following primary infection is not directed against the known major infected cell or virion glycoprotein surface antigens but rather against an internal capsid protein of HSV.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2409225     DOI: 10.1002/jmv.1890160207

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  12 in total

1.  Conserved antigenic and functional domains on glycoprotein B of herpes simplex virus 1 and bovine herpesvirus 2. Brief report.

Authors:  F Conraths; M Ackermann; H Ludwig; G Pauli; L Pereira
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

2.  Glycoprotein B of herpes simplex virus type 1 oligomerizes through the intermolecular interaction of a 28-amino-acid domain.

Authors:  S Laquerre; S Person; J C Glorioso
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

3.  Humoral and cell-mediated immune responses to the glycoproteins of infectious laryngotracheitis herpesvirus.

Authors:  J J York; K J Fahey
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

4.  HSV-1 gB and VZV gp-II crossreactive antibodies in human sera.

Authors:  J E Kühn; K Klaffke; K Munk; R W Braun
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

5.  Serological evidence for variation in the incidence of herpesvirus infections in different species of apes.

Authors:  R Eberle; J K Hilliard
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

6.  Simian alphaherpesviruses and their relation to the human herpes simplex viruses.

Authors:  J K Hilliard; D Black; R Eberle
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

7.  Antibody activity to herpes simplex virus in mouse Ig classes and IgG subclasses.

Authors:  R R McKendall; W Woo
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

8.  An automated ELISA using recombinant antigens for serologic diagnosis of B virus infections in macaques.

Authors:  David Katz; Wei Shi; Irina Patrusheva; Ludmila Perelygina; Manjunath S Gowda; Peter W Krug; Chadi N Filfili; John A Ward; Julia K Hilliard
Journal:  Comp Med       Date:  2012-12       Impact factor: 0.982

9.  Reassessing the detection of B-virus-specific serum antibodies.

Authors:  David Katz; Wei Shi; Martin J Wildes; Peter W Krug; Julia K Hilliard
Journal:  Comp Med       Date:  2012-12       Impact factor: 0.982

10.  Relatedness of glycoproteins expressed on the surface of simian herpes-virus virions and infected cells to specific HSV glycoproteins.

Authors:  R Eberle; D Black; J K Hilliard
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.